Trial Profile
A Phase IIb, Multi-Centre, Randomised, Double-Blind, Active-Controlled Trial Comparing the Neuropsychiatric Adverse Event Profile of Etravirine 400mg qd Versus Efavirenz 600mg qd in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in ARV Therapy-naive HIV-1 Infected Subjects.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Etravirine (Primary) ; Efavirenz; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms SENSE
- Sponsors Janssen-Cilag
- 02 Jun 2012 Company added in association field as reported by European Clinical Trials Database.
- 29 Dec 2011 Results assessing the effects of treatment on serum lipids published in the Journal of Antimicrobial Chemotherapy.
- 30 Aug 2011 48 week results published in the journal AIDS.